Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03736928 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 401
- Enrollment target
NCT03736928 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 401 participants.
The verdict
NCT03736928, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 401 participants
- Enrollment target
Study Summary
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
Interventions
- OTHER placebo
- BIOLOGICAL AbobotulinumtoxinA dose level 1 or 2
- BIOLOGICAL AbobotulinumtoxinA dose 3
- BIOLOGICAL AbobotulinumtoxinA dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2018-11-26 |
| Est. Completion | 2020-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03736928
The ClinicalTrials.gov registry entry for NCT03736928 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 401 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT03736928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03736928 about?
NCT03736928 is a clinical study titled "Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines". An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
What is the current status of trial NCT03736928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 401 participants. The study started on 2018-11-26. Estimated completion is 2020-08-20.
What interventions are being tested in trial NCT03736928?
The interventions under investigation include: placebo (OTHER), AbobotulinumtoxinA dose level 1 or 2 (BIOLOGICAL), AbobotulinumtoxinA dose 3 (BIOLOGICAL), AbobotulinumtoxinA dose 4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03736928?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.